A Phase IV, Randomized, Double-Blind, Placebo-Controlled Exploratory Study of Xolair (Omalizumab) for Treatment of Idiopathic Angioedema in Patients Who Remain Symptomatic Despite Current Therapy
Phase of Trial: Phase IV
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Omalizumab (Primary)
- Indications Angioedema
- Focus Therapeutic Use
- 28 Jun 2017 Status changed from not yet recruiting to recruiting.
- 28 Feb 2017 Planned initiation date changed from 1 Dec 2016 to 1 Mar 2017.
- 22 Nov 2016 New trial record